GlaxoSmithKline's India unit eyes sales growth after Novartis vax deal

GlaxoSmithKline's ($GSK) emerging-market vaccines sales have seen better days, thanks to a $489 million bribery probe that recently led to the indictment of the company's former China head. But according to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' ($NVS) non-flu vaccine assets will help it get there. Report